- Lobbying
- pfizer
Lobbying Arrangements Results for 'Pfizer'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details N/A |
Pfizer Animal Health
|
Watson/Mulhern, LLC. | |||
Details medicare/medicaid |
Pfizer
|
Greenlee Partners | |||
Details |
PFIZER, INC
|
THE MCMANUS GROUP | |||
Details |
PFIZER, INC
|
Mayer Brown LLP | |||
Details Federal Motor Carrier Safety Advisory |
Pfizer
|
Manatt, Phelps, and Phillips | |||
Details The merger between Pfizer and Allergan, and related competition issues. |
Pfizer Inc.
|
Bloom Strategic Counsel | |||
Details General corporate |
Pfizer Inc.
|
Singer Consulting LLC | |||
Details Australian government policy on intellectual property and its impact on the Australian healthcare system |
Pfizer Australia Pty Ltd
|
CapitalHill Advisory | |||
Details |
PFIZER, INC.
|
The Nickles Group | |||
Details Issues regarding Russia's WTO accession; Vietnam pharmaceutical regulation; U.S. FTA negotiations |
Pfizer, Inc.
|
SIDLEY AUSTIN LLP | |||
Details Repeal of the Federal Arbitration Act |
Pfizer
|
Shook, Hardy & Bacon, LLP | |||
Details Issues related to the value of pharmaceuticals including developing sustainable models that support innovation. |
Pfizer Inc.
|
CapView Associates LLC (dba CapView Strategies) | |||
Details Medicare payment regulations |
Pfizer
|
FLEISHMAN-HILLARD GOVERNMENT RELATIONS | |||
Details General tax issues. Tax reform. |
Pfizer, Inc.
|
Federal Policy Group, LLC | |||
Details P.L. 111-148, Patient Protection and Affordable Care Act - Issues relating to comprehensive health care reform in the United States. Issues relating to pharmaceuticals and health reform. S 1631, Cu... |
Pfizer
|
Parven Pomper Strategies, Inc. | |||
Details Treatment of third-party assistance in relation to health savings accounts and high deductible health plans |
Pfizer, Inc.
|
Rutledge Policy Group, LLC | |||
Details Matters pertaining to health care reform |
Pfizer Inc.
Pharmaceutical, consumer and animal health products manufacturer |
The Glover Park Group, LLC | |||
Details Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada... |
Pfizer, Inc.
|
SC Partners LLC | |||
Details medicare |
Pfizer
healthcare |
Greenlee Partners, LLC | |||
Details Medicare Coverage and Reimbursement Health Care Reform Follow-on Biologics |
PFIZER INC.
|
FOLEY HOAG LLP | |||
Details Issues related to prevention of emerging infectious diseases; issues related to trade and tariffs; issues related to sustainability; issues pertaining to the farm bill; HR. 1418 and S. 1844 Anima... |
Zoetis
|
The Russell Group, Inc. | |||
Details Issues related to COVID-19 disaster response and pharmaceutical needs, including Operation Warp Speed. Medicare and healthcare policy issues as they relate to drug pricing. |
Pfizer Inc.
|
Miller Strategies, LLC | |||
Details Intellectual property rights in WTO reform WTO Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) |
Pfizer Inc.
|
Crowell & Moring International, LLC | |||
Details Drug pricing. |
Pfizer Inc.
|
FTI Government Affairs | |||
Details Followon Biologics Super MedPAC HRSA - 340B Drug Pricing Program/Pharmacy Affairs |
Pfizer, Inc.
|
AMERICAN CONTINENTAL GROUP | |||
Details Matters pertaining to health care reform |
PFIZER INC.
|
The Glover Park Group LLC | |||
Details General representation of Pfizer on all issues including medicare, medicaid and pharmaceutical research and development. |
Pfizer Inc.
Pharmaceuticals |
Clark & Weinstock | |||
Details healthcare and the pharmaceutical industry |
Pfizer
|
The Raben Group | |||
Details Support increased funding for the CDC National Immunization Program (Sec 317 program). Support increased funding for the CDC National Immunization Program (Sec 317 program) |
Pfizer
|
Cornerstone Government Affairs, Inc. | |||
Details Legislative and regulatory issues related to bioidentical hormone replacement therapies. |
Pfizer (formerly Wyeth)
|
Mager & Associates LLC | |||
Details H.R. 1957 Asbestos Compensation Fairness Act of 2005 H.R. 729 Medicare Drug Cost Credibility Act of 2005, and drug re-importation and medicaid rebate proposals Investigation of COX-2 inhibitors & i... |
Pfizer
Pharmaceudical Corporation |
Mr. Marion Kenneth Bowler | |||
Details Issues related to biodefense legislation. Issues related to drug safety legislation. Issues related to drug user fee registration. Issues related to healthcare legislation. |
PFIZER, INC.
|
ARNOLD & PORTER LLP | |||
Details S. 334 Healthy Americans Act; S. 484 Enhancing Drug Safety and Innovation Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of ... |
Pfizer
|
Davidson & Company | |||
Details International market access and legislative policy |
Pfizer Inc.
Pharmaceuticals |
Parven Pomper Schuyler Inc. | |||
Details Foreign drug price controls, particularly in advanced European and Asian markets; trade barriers; US-Korea FTA; intellectual property rights |
Pfizer, Inc.
Pharmaceutical Company |
Hogan & Hartson LLP | |||
Details Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA Medicare Part D Rebate Reform- PBMs Out-Of-Pocket C... |
PFIZER INC.
|
in-house lobbying | |||
Details Implementation of Public Law No. 111-148, provisions affecting the pharmaceutical industry; prescription drug abuse. Issues related to Medicare/Medicaid reimbursements. |
Pfizer, Inc.
|
DLA Piper LLP (US) | |||
Details Compulsory licensing of US IP by foreign governments; WTO Covid TRIPS waiver proposal; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs |
Pfizer, Inc.
|
Altrius Group, LLC | |||
Details Encouraged the Congress and the Executive Branch to insist that foreign countries implement their obligations under the WTO Intellectual Property (TRIPS) Agreement and other international and bilat... |
PFIZER, INC
|
THE GORLIN GROUP | |||
Details Global Healthcare issues The proliferation of sub-standard copies of medicines |
Pfizer, Inc.
|
BOCKORNY GROUP, INC. | |||
Details Implementation of the drug pricing provisions in the Inflation Reduction Act Access to Prescription Digital Therapeutics Act (H.R. 1458) |
Pfizer
|
FEDERAL HEALTH POLICY STRATEGIES | |||
Details Health care reform legislation, including H.R. 3200, America's Affordable Health Choices Act of 2009. |
Pfizer Inc.
|
Bingham McCutchen LLP | |||
Details Intellectual property provisions in Colombia's National Development Program |
Latin America Health Care Alliance
|
AKIN GUMP STRAUSS HAUER & FELD | |||
Details Issues relating to corporate tax reform |
The Washington Tax Group LLC
|
Baker & McKenzie, LLP | |||
Details Follow developments within the Executive Branch and at WHO and other multilateral organizations relating to international vaccine policy and financing mechanisms for access to advanced vaccines. |
Pfizer (formerly Wyeth)
|
COVINGTON & BURLING LLP | |||
Details P.L. 111-148 Patient Protection and Affordable Care Act P.L. 111-152 Health Care and Education Reconciliation Act of 2010 P.L. 111-5, American Recovery and Reinvestment Act H.R. 4899, FY 2010 Sup... |
Pfizer Inc.
|
PATTON BOGGS LLP | |||
Details Issues related to the taxation of the biopharmaceutical industry including international taxation |
The Washington Tax & Public Policy Group o/b/o Alliance for Biopharma
lobbying firm |
DOMER CONSULTING, LLC | |||
Details Issues pertaining to COVID-19; Inflation Reduction Act; HR 3927/S.2082 (MADE in America Act); HR 1978/S.912-Protecting Seniors through Immunization Act of 2021; HR 3656/S.3087 (Vaccine Access Impro... |
Pfizer Inc.
|
Empire Consulting Group | |||
Details Issues related to drug pricing S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act Outreach regarding Rare Disease and Part-D copay assistan... |
Pfizer
|
Lincoln Policy Group | |||
Details Intellectual property, data exclusivity, and patent eligibility. Prescription drug coverage and payment policies. Issues related to pharmaceutical supply chain transparency and integrity. |
Pfizer Inc.
|
NVG, LLC |